FDA signals flexibility on psychedelic drug review while keeping evidence standards on September 10, 2026 Advice Clinical Trials Hallucinogens ibogaine mental health methylone Midomafetamine National Priority Voucher Psilocybin public hearing regulatory flexibility United States Food and Drug Administration +